Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2002

View Archived Issues

Chest 2002: imatinib mesilate in pulmonary fibrosis

Cost savings reported in COPD patients treated with cilomilast

Omalizumab reported to be as safe as placebo in allergic asthma/rhinitis

COPD and severe burns, two potential new indications for oxandrolone

Cytos and Medarex collaborate for new drug targets in immunological diseases

New alphavbeta6 integrin antagonists in early development at Merck KGaA

Novel MMP inhibitors in AstraZeneca pipeline

Compounds that directly inhibit the androgen receptor discovered at Praecis

New beta3-adrenoceptor agonists covered by Asahi patent

Novel PDE7 inhibitors and their use in arthritis, asthma, etc.

ICAgen claims voltage-dependent KCOs for epilepsy, pain, anxiety, etc.

FDA advisory committee recommends approval of Pegasys in combination with Copegus

Merck KGaA and Grupo Vita announce manufacturing and licensing agreement for Eneas

AnorMED updates status of product development

Chemoprotective agent heads for clinical trials at ProMetic

New biotechnology company receives investment from BTG

New multiclade HIV vaccine holds promise for broad efficacy

Atorvastatin exerts beneficial clinical and immunomodulatory effects in animal models of MS

Albuleukin superior to rIL-2 in mouse model of metastatic melanoma

Microbially produced kappa opioid receptor antagonist identified by Japanese research group

Phase II trial of TNFerade initiated in patients with esophageal cancer

Label change for Biogen's Avonex approved

Scynexis and Roche collaborate to discover and develop agents for CNS and metabolic diseases

ChromaVision and NewBiotics to collaborate on cancer therapeutic development

Grant awarded for first clinical trial of squalamine in the treatment of prostate cancer

Cell Therapeutics earns milestone payment

Ligand restructures Avinza license and supply agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...